Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ranexa Prescribers for Angina: Cardiologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
October 27, 2008
Medtronic Endeavour Failing to Live Up to Expectations
Analysis of: Medtronic Endeavor Heart Stent Tied to Complications | www.bloomberg.com
Author: GLG Expert Contributor
The Endeavour stent appears to have a higher restenosis rate than currently marketed Drug Eluting Stents without the improved safety profile claimed by the company.  This finding is at odds with the companies marketing message to cardiologists.  These studies, along with the introduction of...
May 19, 2008
Obvious answer - wrong question - NO IMPACT on prescribing
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
Author: GLG Expert Contributor
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
April 11, 2008
Second anda half line drug
Analysis of: The Vytorin Saga Continues: Krumholz Strikes Back | www.pharmalot.com
Author: GLG Expert Contributor
The treatment of hyperlipidemia has profound repercussions on cardiovascular disease. The market is huge. I hear that there were 35 million prescriptions for ezetimibe products last year. Although the epidemiological association between LDL and cardiac risk is strong, LDL is an imperfect surrogate for...
February 19, 2008
Need for cardiac evaluation in patients receiving novel cancer treatments
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: GLG Expert Contributor
Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents.  However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...
January 28, 2008
Expect very dramtic and continued decreases in scripts for vytorin and zetia
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: GLG Expert Contributor
I anticipate vytorin and zetia sales will be down substantial when the IMS numbers come out tommorrow, but that this will be only the beginning of a negative trend for these scripts. I list below several reasons why.
January 25, 2008
Questions about bleeding, proper dose and appropriate patient subsets will limit use
Analysis of: Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration | www.pipelinereview.com
Author: GLG Expert Contributor
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....
January 21, 2008
Crestor Trial Timing is Interesting
Analysis of: First Head to Head Study Comparing CRESTOR(TM) and LIPITOR(R) Effects on the Treatment of Atherosclerosis | www.pipelinereview.com
Author: GLG Expert Contributor
The announcement the new trial comparing Lipitor to Crestor  is interesting but not unexpected.  It is timed to end near the end of lipitor's patent. A win- which is likely- will certainly help AZN sell their drug against the much cheaper generic lipitor.
January 21, 2008
Very Interesting Diabetes Data From an Unlikely Source
Analysis of: CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36 | www.pipelinereview.com
Author: GLG Expert Contributor
Impressive data on Ranexa in HGBA1c. The result of a decrease of 0.64 vs baseline and 0.43 vs placebo are at first glance underwhelming.  But a closer looks shows that the results are realy quite impressive
January 18, 2008
Nitromed gone and soon forgotten
Analysis of: Nitromed Halts Marketing of Drug | online.wsj.com
Author: GLG Expert Contributor
Apparently doctors aren't quite as easily manipulated by pharma as we all thought.  Despite a vigorous marketing effort, Bidil was seen by cardiologist as what it is- an expensive combination of two generics and was not used- even after insurance companies started to pay for it.
Samuel ButmanJanuary 17, 2008
First Impressions Carry the Day and the Year -Vytorin Loses in ENHANCE
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: Samuel Butman, Interventional Cardiologist, Verde Valley Heart LLC
The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant.   The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...

Page : 1 2 3 4 Next1 to 10 of 40

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637